Related Experiment Video
Updated: Jul 10, 2026
12:21
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
17.5K
Cabazitaxel's ototoxicity: An animal study and histopathologic research
Abdulkadir Bucak1, Çiğdem Özdemir2, Abdullah Kınar3
1Department of Ear Nose and Throat Head and Neck Diseases, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.
Journal of Cancer Research and Therapeutics
|May 6, 2023
Summary
Cabazitaxel (CBZ) chemotherapy can cause hearing damage (ototoxicity) in rats. This ototoxic effect on the cochlea worsened with higher doses, indicating a potential risk for patients.
Area of Science:
- Ototoxicology
- Pharmacology
- Oncology
Background:
- Chemotherapeutic agents can cause ototoxicity, a form of hearing damage, through direct toxicity or metabolic disruption.
- Cabazitaxel (CBZ) is a potent chemotherapeutic agent used for prostate cancer, particularly in cases resistant to other treatments.
- Understanding the ototoxicity profile of CBZ is crucial for patient safety and treatment management.
Purpose of the Study:
- To investigate the ototoxicity of Cabazitaxel (CBZ) in a preclinical rat model.
- To evaluate the dose-dependent effects of CBZ on cochlear structures.
- To assess the potential for CBZ-induced hearing damage.
Main Methods:
- Twenty-four male Wistar-Albino rats were divided into four groups.
- Three groups received intraperitoneal Cabazitaxel (CBZ) at varying doses (0.5, 1.0, 1.5 mg/kg/week) for four weeks.
- The control group received saline; cochleae were examined histopathologically.
Main Results:
- Intraperitoneal administration of Cabazitaxel (CBZ) demonstrated ototoxic effects in rats.
- Histopathological examination revealed a dose-dependent worsening of cochlear damage.
- Statistical analysis confirmed a significant effect (P < 0.05).
Conclusions:
- Cabazitaxel (CBZ) may possess ototoxic properties, leading to cochlear damage.
- The ototoxicity of CBZ appears to be dose-dependent.
- Further clinical studies are warranted to elucidate the ototoxicity of CBZ in human patients.
